Brief: Reneo Pharmaceuticals Announces Last Patient Last Visit In The Pivotal Stride Study Of Mavodelpar In Primary Mitochondrial Myopathies

Onkure Therapeutics

09/10/2023 12:58

Oct 9 (Reuters) - Reneo Pharmaceuticals Inc  RPHM.O :
    * RENEO PHARMACEUTICALS ANNOUNCES LAST PATIENT LAST VISIT IN
THE
PIVOTAL STRIDE STUDY OF MAVODELPAR IN PRIMARY MITOCHONDRIAL
MYOPATHIES (PMM)
    * RENEO PHARMACEUTICALS INC - TOPLINE DATA RESULTS FROM
STRIDE
STUDY ARE EXPECTED IN DECEMBER 2023
    * RENEO PHARMACEUTICALS INC - STRIDE AND STRIDE AHEAD
STUDIES WILL
FORM BASIS OF NDA TO FDA, PLANNED FOR SUBMISSION IN H1 2024

Source text for Eikon:  ID:nGNX6cg1z8 
Further company coverage:  RPHM.O 

 ((Reuters.Briefs@thomsonreuters.com))